Send to

Choose Destination
See comment in PubMed Commons below
Oncogene. 2014 Feb 20;33(8):1006-16. doi: 10.1038/onc.2013.31. Epub 2013 Feb 25.

CD84 is a survival receptor for CLL cells.

Author information

Department of Immunology, Weizmann Institute of Science, Rehovot, Israel.
Hematology Institute, Kaplan Medical Center, Rehovot, Israel.
Department of Hematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Garden State Cancer Center, Center for Molecular Medicine and Immunology, Morris Plains, NJ, USA.
Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.


Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of CD5+ B lymphocytes in peripheral blood, lymphoid organs and bone marrow. The main feature of the disease is accumulation of the malignant cells due to decreased apoptosis. CD84 belongs to the signaling lymphocyte activating molecule family of immunoreceptors, and has an unknown function in CLL cells. Here, we show that the expression of CD84 is significantly elevated from the early stages of the disease, and is regulated by macrophage migration inhibitory factor and its receptor, CD74. Activation of cell surface CD84 initiates a signaling cascade that enhances CLL cell survival. Both downmodulation of CD84 expression and its immune-mediated blockade induce cell death in vitro and in vivo. In addition, analysis of samples derived from an on-going clinical trial, in which human subjects were treated with humanized anti-CD74 (milatuzumab), shows a decrease in CD84 messenger RNA and protein levels in milatuzumab-treated cells. This downregulation was correlated with reduction of Bcl-2 and Mcl-1 expression. Thus, our data show that overexpression of CD84 in CLL is an important survival mechanism that appears to be an early event in the pathogenesis of the disease. These findings suggest novel therapeutic strategies based on the blockade of this CD84-dependent survival pathway.

[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Nature Publishing Group Icon for PubMed Central
    Loading ...
    Support Center